ArticleImmunity, inflammation and disease2026
The Clinical Utility of Labial Gland Biopsy in Patients With Suspected Neuro-Sjögren.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeuro-Sjögren, the neurological subtype of Sjögren's Disease (SjD), is difficult to diagnose due to its heterogeneity and diverse manifestations. While the diagnostic role of labial gland biopsy (LGB) in SjD is established, its significance in Neuro-Sjögren remains unclear.
objectiveTo assess the diagnostic utility of LGB in patients with suspected Neuro-Sjögren.
methodsWe conducted a retrospective cross-sectional study at Xuanwu Hospital, Capital Medical University (2019-2023). Of 456 patients with suspected SjD, 135 were classified as suspected Neuro-Sjögren and 277 as suspected non-Neuro-Sjögren. According to our center's diagnostic pathway, with reference to the 2016 ACR/EULAR criteria, patients were categorized into LGB-required (n = 91) and non-LGB-required (n = 44) groups. Logistic regression identified factors associated with LGB requirement. LGB-required patients were further stratified into LGB-positive (n = 74) and LGB-negative (n = 17) for clinical and laboratory comparison.
resultsSuspected Neuro-Sjögren patients demonstrated higher LGB requirement (67.4% vs. 56.3%, p = 0.031) and positivity (81.3% vs. 51.3%, p < 0.001) compared with suspected non-Neuro-Sjögren patients. Independent factors associated with biopsy requirement included younger age at onset and early-onset neurological symptoms, whereas anti-SSB positivity and ANA titers ≥ 1:320 were associated with a lower likelihood of requiring biopsy. LGB-positive patients more frequently showed non-specific inflammatory or immunologic abnormalities, including higher erythrocyte sedimentation rate, elevated serum IgG, and higher antinuclear antibody titers (≥ 1:320).
conclusionLGB may provide supportive information as part of the diagnostic work-up in selected patients with suspected Neuro-Sjögren, particularly when serological findings are negative or inconclusive. Associations with LGB requirement should be interpreted in the context of the center-specific diagnostic pathway and should not be regarded as universal indications for biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.